Does PT-141 really work?
There is human research behind bremelanotide, the molecule also called PT-141. The useful question is what it showed, in whom, and whether it applies to the treatment you are considering.
The strongest evidence
In two 24-week randomized trials, injected bremelanotide improved measured sexual desire and reduced distress about low desire compared with placebo in premenopausal women with acquired, generalized HSDD. The trials randomized 1,267 women. The difference in the number of satisfying sexual events was not statistically significant. Read the study and its results.
Those are specific benefits measured in a defined population. They support a conversation about desire; they do not promise a particular experience each time someone uses treatment.
What does that mean for the product offered here?
Vyleesi is FDA-approved for acquired, generalized HSDD in certain premenopausal women. Its indication excludes low desire caused by another medical or psychiatric condition, a relationship problem, or a medication or substance. It is not approved for sexual-performance enhancement or postmenopausal women. See the approved indication.
AnthologyRX offers a compounded PT-141 injection after clinician review. It is not Vyleesi and is not FDA-approved. Published results for a manufactured drug do not establish equivalent results for a compounded preparation. Learn how FDA distinguishes compounded drugs.
Does PT-141 work for men?
Early human research studied both subcutaneous PT-141 and intranasal PT-141 in men, including men with erectile dysfunction. These studies examined erectile responses, drug exposure and tolerability. They are not large trials establishing reliable treatment of low desire in men or outcomes for our compounded product.
Route matters too. A nasal study is evidence about that nasal preparation, not proof that every spray or injection works the same way. Ask your clinician which evidence applies to the exact formulation and concern being treated.
Why do individual reviews sound so different?
A review rarely gives you the full picture: the actual product, concentration, route, health history, other treatments or what the person hoped would change. A story about a stronger erection is also answering a different question from a story about renewed interest in sex.
Use those stories to identify questions you want answered. Use the clinical evidence and your own Assessment to evaluate the treatment.
Desire and erections are different conversations
Tell your clinician what has changed in everyday language: less interest, difficulty getting or keeping an erection, discomfort, or a combination. You do not need to arrive with a diagnosis. Our PT-141, sildenafil and tadalafil comparison explains the different treatment approaches.
Benefits belong alongside tolerability. Read the PT-141 safety guide before deciding what you want to discuss.
Sources
- Kingsberg et al. Two randomized phase 3 bremelanotide trials
Obstetrics & Gynecology, 2019. DOI: 10.1097/AOG.0000000000003500.
- Vyleesi prescribing information
DailyMed. Indication, contraindications, adverse reactions and interactions.
- Rosen et al. Subcutaneous PT-141 in healthy men and men with ED
International Journal of Impotence Research, 2004. Early safety and pharmacodynamic research.
- Diamond et al. Intranasal PT-141 in healthy men and men with ED
International Journal of Impotence Research, 2004. A different route from the injection offered here.
- FDA: Compounding questions and answers
The distinction between compounded medications and FDA-approved drug products.
